Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03737370 · ClinicalTrials.gov registry record · Phase 1
Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT03737370 is a Phase 1 study that has completed, run by Tufts Medical Center. The registered enrollment target is 43 participants.
The verdict
NCT03737370, a Phase 1 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
The objective of this study is to determine the maximum safe dose of Ra-223 in combination with fractionated (split doses) docetaxel when given to subjects and to determine the best administering dose. The study will look at side effects that may happen while taking the combination treatment. A total of approximately 18 subjects will take part in the dose escalation part of the study and an additional 25 subjects will participate in the expansion cohort. This study will be conducted across four centers in the United States.
Interventions
- DRUG Docetaxel
- RADIATION Radium 223
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2018-01-30 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03737370
The ClinicalTrials.gov registry entry for NCT03737370 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT03737370 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03737370 about?
NCT03737370 is a clinical study titled "Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer". The objective of this study is to determine the maximum safe dose of Ra-223 in combination with fractionated (split doses) docetaxel when given to subjects and to determine the best administering dose. The study will look at side effects that may happen while taking the combination treatment. A tota...
What is the current status of trial NCT03737370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2018-01-30. Estimated completion is 2025-09-30.
What interventions are being tested in trial NCT03737370?
The interventions under investigation include: Docetaxel (DRUG), Radium 223 (RADIATION).
Who is sponsoring clinical trial NCT03737370?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.